簡介: | Colon Cancer qBiomarker Mutation PCR Array 結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片 |
提供商: | SAbiosciences |
服務(wù)名稱: | 結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片 |
地區(qū): | 美國 |
“英拜為您實驗加速” 技術(shù)服務(wù)網(wǎng)址:http://kwbcf.com/ 服務(wù)熱線:400-696-6643、 18019265738 郵箱:daihp@yingbio.com 、 huizhang1228@foxmail.com Colon Cancer qBiomarker Mutation PCR Array 結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片
結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片是一個翻譯研究的工具,允許快速、準(zhǔn)確、全面的分析在人類結(jié)腸癌樣本中前體細(xì)胞的基因突變:APC,BRAF,CTNNB1 /β-連環(huán)蛋白FBXW7, KRAS, PIK3CA, SRC, and P53。這些突變保證廣泛的研究,以提高致癌作用的理解和鑒定潛在的藥物靶點。已有許多研究通過單個和多個體細(xì)胞突變狀態(tài)信息鑒定關(guān)鍵信號轉(zhuǎn)導(dǎo)中斷。例如,EGFR和KRAS基因的突變狀態(tài)可以預(yù)測某些藥物針對這些分子的生理反應(yīng)。人類結(jié)腸癌qBiomarker體細(xì)胞突變PCR芯片以其全面的內(nèi)容覆蓋范圍,用于研究結(jié)腸癌背景下的基因突變,有可能發(fā)現(xiàn)和鑒定結(jié)腸癌和這些突變已確定的其他癌癥的藥物靶標(biāo)。這個芯片包含86個DNA突變序列用于檢測最頻繁的、能性驗證、在人類結(jié)腸癌癥中有生物學(xué)意義的突變。這些突變的選擇根據(jù)全面的體細(xì)胞突變數(shù)據(jù)庫和同行評審的科學(xué)文獻(xiàn),來自29,000多個結(jié)腸癌樣本發(fā)生最頻繁重復(fù)編譯的體細(xì)胞突變。簡單的產(chǎn)品模式和操作程序讓任何一個具備實時定量PCR儀的實驗室都可進行常規(guī)的體細(xì)胞突變分析。 APC: 34 Assays The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578. BRAF: 1 Assay In colon cancer, the BRAF mutation that leads to increased kinase activity, p. V600E mutation, is the most important to test. CTNNB1: 5 Assays The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta. FBXW7: 1 Assay The mutations queried by these assays lay in either the third or fourth repeat of the protein's WD40 domain, typically involved in protein-protein interactions. KRAS: 17 Assays The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP. PIK3CA: 7 Assays The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors. SRC: 1 Assay SRC is a proto-oncogene and a tyrosine-protein kinase that plays a role in the regulation of embryonic development and cell growth. Mutations in this gene could be involved in the malignant progression of colon cancer. TP53: 20 Assays The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure. 工作原理: Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol
Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol. Principle of Mutant Discrimination with ARMS? |